Alnylam Pharmaceuticals, Inc. $ALNY Shares Acquired by Forsta AP Fonden

Forsta AP Fonden lifted its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 2.3% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 26,400 shares of the biopharmaceutical company’s stock after buying an additional 600 shares during the quarter. Forsta AP Fonden’s holdings in Alnylam Pharmaceuticals were worth $8,609,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. National Pension Service lifted its holdings in Alnylam Pharmaceuticals by 0.8% in the second quarter. National Pension Service now owns 175,046 shares of the biopharmaceutical company’s stock valued at $57,081,000 after acquiring an additional 1,387 shares during the period. Cascade Financial Partners LLC purchased a new position in shares of Alnylam Pharmaceuticals in the 2nd quarter valued at about $204,000. Vise Technologies Inc. acquired a new stake in shares of Alnylam Pharmaceuticals in the second quarter valued at about $435,000. Allworth Financial LP boosted its holdings in Alnylam Pharmaceuticals by 11.8% during the second quarter. Allworth Financial LP now owns 691 shares of the biopharmaceutical company’s stock worth $225,000 after buying an additional 73 shares in the last quarter. Finally, Fidelis Capital Partners LLC acquired a new position in Alnylam Pharmaceuticals during the second quarter worth about $175,000. Institutional investors and hedge funds own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Price Performance

Shares of NASDAQ:ALNY opened at $453.97 on Friday. The company has a debt-to-equity ratio of 4.10, a quick ratio of 2.75 and a current ratio of 2.80. The business’s fifty day moving average price is $458.86 and its two-hundred day moving average price is $381.74. The stock has a market cap of $59.98 billion, a PE ratio of -183.79 and a beta of 0.30. Alnylam Pharmaceuticals, Inc. has a one year low of $205.87 and a one year high of $495.55.

Analysts Set New Price Targets

ALNY has been the subject of a number of research reports. UBS Group lifted their price target on shares of Alnylam Pharmaceuticals from $403.00 to $550.00 and gave the company a “buy” rating in a research report on Friday, August 1st. Morgan Stanley raised their price objective on Alnylam Pharmaceuticals from $405.00 to $475.00 and gave the company an “equal weight” rating in a research note on Monday, October 6th. Canaccord Genuity Group lifted their price objective on Alnylam Pharmaceuticals from $390.00 to $415.00 and gave the stock a “buy” rating in a report on Friday, August 1st. Truist Financial boosted their target price on Alnylam Pharmaceuticals from $459.00 to $535.00 and gave the stock a “buy” rating in a research report on Friday, October 17th. Finally, Oppenheimer restated an “outperform” rating and issued a $500.00 price target on shares of Alnylam Pharmaceuticals in a research report on Friday, October 31st. Twenty-three research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Alnylam Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $482.17.

Insider Buying and Selling at Alnylam Pharmaceuticals

In related news, EVP Jeffrey V. Poulton sold 3,821 shares of the stock in a transaction on Thursday, October 2nd. The stock was sold at an average price of $452.05, for a total transaction of $1,727,283.05. Following the sale, the executive vice president owned 54,052 shares of the company’s stock, valued at $24,434,206.60. This trade represents a 6.60% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Tolga Tanguler sold 1,405 shares of the business’s stock in a transaction dated Thursday, October 2nd. The shares were sold at an average price of $452.05, for a total transaction of $635,130.25. Following the completion of the transaction, the executive vice president directly owned 27,438 shares of the company’s stock, valued at $12,403,347.90. The trade was a 4.87% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 66,696 shares of company stock valued at $30,430,694. 1.20% of the stock is owned by company insiders.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.